6123329081

T-563 P.030/031 F-843

Sheet 1 of 2

Date Mailed: OCTOBER 1, 2003

FORM 1449*

INFORMATION DISCLOSURE STATEMENT Docket Number: Application Number: 11669.132USC1 09/520,130

IN AN APPLICATION

(Use several sheets if necessary)

Applicant: ARATHOON ET AL.

Filing Date: MARCH 7, 2000 Group Art Unit: 1642

Customer No. 23552

	<u> </u>	τ	J.S. PATENT DOCUMEN				
EXAMINÉR INITIAL	DOCUMENT NO	DATE	NAME	CLASS	CLASS SUBCLASS FILING IF APPRO		
MH	5,731,168	03/1998	CARTER ET AL.				
17/14	5,821,333	10/1998	CARTER ET AL.	_			
			REIGN PATENT DOCUM	GENTS			
		· — —	<u> </u>	UNTRY CLASS	SUBCLASS	TRANSLATION	
	DOCUMENT NO	DATE	COUNTRY			YES	NO
				<u> </u>			
"	OTH	ER DOCUMEN	TS (Including Author, Title,	Date, Pertinent	Pages, Etc.)		
ALI	fluore	Bedzyk et al., "Active Site Structure and Antigen Binding Properties of Idiotypically Cross-reactive Anti- fluorescein Monoclonal Antibodics", The Journal of Biological Chemistry, 265(1):133-138 (1990)					
MH	Cance	Bryunck, A. et al., "Characterisation of a humanized bispecific monoclongal antibody for cancer therapy", <u>Br. J.</u> <u>Cancer</u> , 67:436-440 (1993)					
Art	Hema	Carter, P. et al., "Toward The Production of Bispecific Antibody Fragments for Clinical Applications", <u>J.</u> Hematotherapy, 4(5):463-470 (Oct. 1995)					
Art	(Aug	Carter, P. et al., "Engineering antibodies for imaging and therapy", Curr. Opin. Biotechnology, 8(4):449-454 (Aug. 1997)					
ArH	De Jo	De Jonge, J. et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments", Mol. Jimmunol., 32(17-18):1405-1412 (Dec. 1995)					
MH	Godd	Goddard et al., NCBI Genbank AF048774 (1998)					
MU	Gode	Goddard et al., NCBI Genbank AF048775 (1998)					
Alt	throu Cher	Gulliver, G. et al., "Conversion of an Anti-single-stranded DNA Active Site to an Anti-fluorescein Active Site through Heavy Chain Complementarity Determining Region Transplantation", The Journal of Biological Chemistry, 269(11):7934-7940 (1994)					
All	on L	Gulliver, G. et al., "Effect of Transplantation of Antibody Heavy Chain Complementarity Determining Regions on Ligand Binding", The Journal of Biological Chemistry, 269(39):24040-24045 (Sept. 30, 1994)					
AUH	Kria	Kriangkum, J. et al, "Bispecific and bifunctional single chain recombinant antibodies", Bjomolecular Engineering, 18(1):31-40 (Aug. 2001)					

	DATE CONSIDERED	3/22/04
EXAMINER: Initial if reference considered, whether or not citation is in con and not considered. Include copy of this form for next communication to the	nformance with MPEP 609; dr ne Applicant.	aw line through citation if not in conformance

*Substitute Disclosure Statement Form (PTO-1449)

. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

6123329081

Customer No. 23552

T-563 P.031/031 F-843

Sheet 2 of 2

Date Mailed: OCTOBER 1, 2003

Date Mariet, Coloration,			
FORM 1449*	INFORMATION DISCLOSURE STATEMENT	Docket Number: 11669.132USC1	Application Number: 09/520,130
	IN AN APPLICATION	Applicant: ARATHOON ET A Filing Date: MARCH 7, 2000	
1	(Use several sheets if necessary)	I ming water. Ivil the transfer	

	1 4 702
MH	Mallender, W. et al., "Comparative Properties of the Single Chain Antibody and Fv Derivatives of mAb 4-4-20", The Journal of Biological Chemistry, 271(10):5338-5346 (March 8, 1996)
AH	Mallender, W. et al., "Construction, Expression, and Activity of a Bivalent Bispecific Single-chain Antibody", The Journal of Biological Chemistry, 269(1):199-206 (Jan. 7, 1994)
Aut	Massino et al., "Quantitative analysis of the products of IgG chain recombination in hybrid hybridomas based on affinity chromatography and tadioimmunoassay", Journal of Immunological Methods, 201:57-66 (1997)
AU	Merchant et al., "An efficient route to human bispecific lgG", Nature Biotechnology, 16:677-681 (July 1998)
MIH	Muller, KM et al., "The first constant domain (C _H 1 and C _L) of an antibody used as heterodimerization domain for hispecific miniantibodies", FEBS Letter, 422(2):259-264 (January 30, 1998)
MH	Muller, KM et al., "A dimeric bispecific miniantibody combines two specificities with avidity", FEBS Letter, 432(1-2):45-49 (July 31, 1998)
AZH.	Pluckthun, A. et al., "New protein engineering approaches to multivalent and bispecific antibody fragments", Immunotechnology, 3(2):83-105 (June 1997)
Alt	Reddy, V. et al., "Production of Hybrids Secreting Bispecific Antibodies Recognising CEA and Doxorubicin", Anticancer Research, 13:2077-2084 (1993)
ALH	Segal, DM et al., "Introduction: bispecific antibodies", J. Immunol. Methods, 248(1-2):1-6 (Feb. 1, 2001)
ALH	Smith et al., "Variable Region Primary Structures of Monoclonal Anti-DNA Autoantibodies from NZB/NZW F ₁ Mice", Molecular Immunology, 27(5):463-470 (1990)
A14	Tomlinson, IM et al., "The structural repertoire of the human V _K domain", EMBO Journal, 14(18):4628-4638 (Sept. 15, 1995)
AH	Tomlinson, I. et al., "Methods for Generating Multivalent and Bispecific Antibody Fragments", Methods Enzymol., 326:461-479 (2000)
Aut	Tso, JY et al., "Preparation of a Bispecific F(ab') ₂ Targeted to the Human IL-2 Receptor", J. Hematotherapy, 4(5):389-394 (Oct. 1995)
Art	Vuillez, J. et al., "Two-Step Immunoscintigraphy for Non-Small-Cell Lung Cancer Staging Using a Bispecific Anti-CEA/Anti-Indium-DTPA Antibody and an Indium-111-Labeled DTPA Dimer", The Journal of Nuclear Medicine, 38(4):507-511 (April 1997)
	1

	O	1 Helleran	DATE CONSIDERED	3/22/04
EXAMINER	<u> </u>		A LIDEO COOL	trow line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.